Patheon Builds Lyophilization
06 May 2002 00:00 [Source: ICB Americas]
Patheon Inc., the Toronto, Canada-based provider of pharmaceutical
contract manufacturing services, has expanded its European
lyophilization capabilities by acquiring a 144,000 square foot
sterile manufacturing facility in Ferentino, Italy, from Biomedica
Foscama SpA. The move will lift the company's total lyophilization
capacity to roughly 125 square meters, and plans call for
increasing that to nearly 250 square meters by 2004.
"The acquisition of this facility is part of Patheon's strategy to
serve the needs of the industry's innovators with higher-value
services, says Robert Tedford, CEO. "Used in the manufacture of
sterile injectable pharmaceutical products, lyophilization is a
process during which products that are unstable in liquid form are
freeze-dried to remove water and improve their stability."
Mr. Tedford notes that demand for lyophilization has grown among
both biotech and large pharmacuetical companies. Patheon's own
capacity is fully utilized. Additional capacity will come on line
at Monza, Italy, in the third quarter, but Mr. Tedford expects it
to be almost sold out. The Ferentino facility will provide
additional capacity when it opens in 2003, and Patheon has
committed to doubling the site's existing capacity by adding
another unit. Including the Ferentino acquisition, the company
plans to invest $40 million this year and next on
In 2001, lyophilization contributed C$12 million ($7.7 million) to
revenues at Patheon, and the company expects that figure to
increase to C$50 million in 2005.
"This investment program positions Patheon to become a preeminent
European supplier of lyophilization services," says Mr. Tedford.
For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial
to ICIS news - the breaking online news service for the global chemical industry.
Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free
trial to ICIS Chemical Business.